Research programme: cyclophilin ligands - Guilford PharmaceuticalsAlternative Names: Cyclophilin ligands
Latest Information Update: 18 Jun 2004
At a glance
- Originator MGI GP
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Age-related macular degeneration; Neurological disorders
Most Recent Events
- 18 Jun 2004 Discontinued - Preclinical for Age-related macular degeneration in USA (unspecified route)
- 18 Jun 2004 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)
- 17 Nov 2003 Preclinical trials in Age-related macular degeneration in USA (unspecified route)